PharmTech Drug Digest 11.20
News|Articles|October 9, 2013

Catalent Aquires Relthy to Expand South American Business

Catalent has acquired Relthy Laboratorios in Brazil to expand its South American softgel technology business.

Catalent Pharma Solutions has aquired Relthy Laboratórios in Brazil to expand its softgel technology business. The deal follows Catalent’s recent expansion into China, with softgel and clinical trial supply operations.

Catalent acquired 100% of the shares in the Indaiatuba-based, privately held company. Founded in 1988, Relthy produces softgel encapsulated vitamin, mineral and supplement (VMS) products for the Brazilian market, but also supplies products for the prescription and over-the-counter (OTC) segments. Relthy becomes Catalent’s 11th softgel facility adding to its existing pharmaceutical and OTC-focused South American facilities, located in Sorocaba, Brazil, and Buenos Aires, Argentina.

Relthy employs 350 staff and has annual production capacity of approximately 2 billion capsules per annum. The deal further expands Catalent's position into the VMS nutritional market while simultaneously expanding its primary and secondary packaging capabilities in the country. Relthy’s management team will join Catalent.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.